MYRIAD GENETICS Projects Strong 2026 Growth with 43% Adjusted EBITDA Increase

summarizeSummary

Myriad Genetics announced preliminary Q4 and full-year 2025 revenues and introduced optimistic full-year 2026 financial guidance, projecting significant Adjusted EBITDA growth.

check_boxKey Events

• Preliminary 2025 Revenue Reported

  Myriad Genetics reported preliminary Q4 2025 revenue between $207 million and $209 million, and full-year 2025 revenue between $822 million and $824 million.

• Introduced 2026 Financial Guidance

  The company introduced full-year 2026 revenue guidance of $860 million to $880 million and Adjusted EBITDA guidance of $37 million to $49 million.

• Significant Adjusted EBITDA Growth Projected

  The mid-point of the 2026 Adjusted EBITDA guidance reflects an approximate 43% increase compared to the mid-point of the previous full-year 2025 guidance range.

• Mixed 2025 Test Volume Growth

  Preliminary 2025 total test volumes increased 1% year-over-year, driven by 7% growth in hereditary cancer and 6% in mental health testing, but offset by a 4% decrease in prenatal health testing.

auto_awesomeAnalysis

This 8-K provides an early look at Myriad Genetics' financial performance and a strong outlook for 2026. The projected 43% growth in Adjusted EBITDA for 2026 is a significant positive signal, indicating expected improvements in profitability and operational efficiency. While the 2025 preliminary results are subject to audit, the early release of guidance, particularly the robust EBITDA forecast, suggests management confidence in future performance. Investors will likely view the strong profitability guidance favorably, despite mixed test volume growth in 2025.